全文获取类型
收费全文 | 47926篇 |
免费 | 3431篇 |
国内免费 | 1350篇 |
专业分类
耳鼻咽喉 | 433篇 |
儿科学 | 1049篇 |
妇产科学 | 575篇 |
基础医学 | 3750篇 |
口腔科学 | 1592篇 |
临床医学 | 5578篇 |
内科学 | 10822篇 |
皮肤病学 | 1158篇 |
神经病学 | 2008篇 |
特种医学 | 1963篇 |
外科学 | 3886篇 |
综合类 | 7301篇 |
一般理论 | 4篇 |
预防医学 | 5901篇 |
眼科学 | 907篇 |
药学 | 3322篇 |
39篇 | |
中国医学 | 1863篇 |
肿瘤学 | 556篇 |
出版年
2023年 | 960篇 |
2022年 | 1588篇 |
2021年 | 2245篇 |
2020年 | 2241篇 |
2019年 | 1890篇 |
2018年 | 1812篇 |
2017年 | 1692篇 |
2016年 | 1600篇 |
2015年 | 1582篇 |
2014年 | 3448篇 |
2013年 | 3511篇 |
2012年 | 2805篇 |
2011年 | 3121篇 |
2010年 | 2481篇 |
2009年 | 2395篇 |
2008年 | 2350篇 |
2007年 | 2229篇 |
2006年 | 1875篇 |
2005年 | 1746篇 |
2004年 | 1357篇 |
2003年 | 1205篇 |
2002年 | 1005篇 |
2001年 | 951篇 |
2000年 | 759篇 |
1999年 | 569篇 |
1998年 | 516篇 |
1997年 | 430篇 |
1996年 | 297篇 |
1995年 | 395篇 |
1994年 | 349篇 |
1993年 | 247篇 |
1992年 | 253篇 |
1991年 | 232篇 |
1990年 | 190篇 |
1989年 | 205篇 |
1988年 | 185篇 |
1987年 | 169篇 |
1986年 | 140篇 |
1985年 | 175篇 |
1984年 | 203篇 |
1983年 | 161篇 |
1982年 | 142篇 |
1981年 | 153篇 |
1980年 | 114篇 |
1979年 | 136篇 |
1978年 | 112篇 |
1977年 | 102篇 |
1976年 | 103篇 |
1975年 | 94篇 |
1974年 | 73篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
真空辅助乳腺活检系统( VABB)由美国食品与药品监督管理局于 1995年批准应用于乳腺肿物的活检。该系统包括内外套针、旋切刀、传送装置、真空抽吸泵、控制器及相关软件等组成。 VABB可在多种影像学引导下(乳腺超声、 MRI、X线)对乳腺病灶切除活检。起初 VABB系统主要应用于乳腺病灶的活检,如早期乳腺癌的诊断。由于 VABB通过影像学引导下精确完整切除病灶,能够获得足够量的组织样本进行病理学检查,因此广泛应用于良性乳腺疾病的治疗,如良性乳腺肿瘤的切除、乳腺炎、乳腺整形手术等,成为乳腺微创手术的重要手段。 相似文献
3.
目的结合文献回顾观察Aicardi-Goutières综合征(AGS)影像学表现。方法回顾性分析3例经基因检测证实的AGS患儿,患儿月龄分别为3、5、8个月,均接受颅脑MR检查,其中1例(病例3)接受颅脑CT检查,结合文献分析其颅脑MRI及CT表现。结果颅脑MRI显示,病例1双侧侧脑室、双侧额颞部脑外间隙增宽;病例2未见明显异常;病例3脑萎缩,双侧侧脑室前角旁异常呈T1WI等信号、T2WI及T2-液体衰减翻转恢复(T2-FLAIR)序列呈稍高信号。颅脑CT显示病例3脑萎缩,双侧基底核区、双侧侧脑室前角旁钙化,双侧侧脑室前角旁低密度灶。结论颅内钙化、脑萎缩和脑白质营养不良为AGS常见影像学表现。 相似文献
4.
Alzina Koric MPP Chun-Pin Chang PhD Bayarmaa Mark MS Kerry Rowe PhD John Snyder PhD Mark Dodson MD Vikrant G. Deshmukh PhD Michael G. Newman MS Alison M. Fraser MPH Ken R. Smith PhD Ankita P. Date MS Lisa H. Gren PhD Christina A. Porucznik PhD Benjamin A. Haaland PhD N. Lynn Henry MD Mia Hashibe PhD 《Cancer》2022,128(14):2826-2835
5.
6.
《Nutrition, metabolism, and cardiovascular diseases : NMCD》2022,32(1):21-31
AimThis review aims to summarize and discuss some of the most relevant clinical trials in epidemiology, diagnostics, and treatment of hypertension published in 2020 and 2021.Data synthesisThe trials included in this review are related to hypertension onset age and risk for future cardiovascular disease, reliability of different blood pressure monitoring methods, role of exercise-induced hypertension, treatment of hypertension in patients with SARS-CoV-2 infection, management of hypertension high-risk patient groups, e.g., in the elderly (≥80 years) and patients with atrial fibrillation, and the interplay between nutrition and hypertension, as well as recent insights into renal denervation for treatment of hypertension.ConclusionsHypertension onset age, nighttime blood pressure levels and a riser pattern are relevant for the prognosis of future cardiovascular diseases. The risk of coronary heart disease appears to increase linearly with increasing exercise systolic blood pressure. Renin-angiotensin system blockers are not associated with an increased risk for a severe course of COVID-19. In elderly patients, a risk-benefit assessment of intensified blood pressure control should be individually evaluated. A J-shaped association between cardiovascular disease and achieved blood pressure could also be demonstrated in patients with atrial fibrillation on anticoagulation. Salt restriction and lifestyle modification remain effective options in treating hypertensive patients at low cardiovascular risk. Sodium glucose co-transporter 2 inhibitors and Glucagon-like peptide-1 receptor agonists show BP-lowering effects. Renal denervation should be considered as an additional or alternative treatment option in selected patients with uncontrolled hypertension. 相似文献
7.
Henry Velazquez-Soto Fernanda Real Maria C Jim nez-Mart nez 《World Journal of Immunology》2022,12(1):1-8
Co-stimulatory molecules are key mediators in the regulation of immune responses and knowledge of its different families, structure, and functions has improved in recent decades. Understanding the role of co-stimulatory molecules in pathological processes has allowed the development of strategies to modulate cellular functions. Currently, modulation of co-stimulatory and co-inhibitory molecules has been applied in clinical applications as therapeutic targets in diseases and promising results have been achieved. 相似文献
9.
Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder. Cardiometabolic and genetic risk factors play an important role in the trajectory of AD. Cardiometabolic risk factors including diabetes, mid-life obesity, mid-life hypertension and elevated cholesterol have been linked with cognitive decline in AD subjects. These potential risk factors associated with cerebral metabolic changes which fuel AD pathogenesis have been suggested to be the reason for the disappointing clinical trial results. In appreciation of the risks involved, using search engines such as PubMed, Scopus, MEDLINE and Google Scholar, a relevant literature search on cardiometabolic and genetic risk factors in AD was conducted. We discuss the role of genetic as well as established cardiovascular risk factors in the neuropathology of AD. Moreover, we show new evidence of genetic interaction between several genes potentially involved in different pathways related to both neurodegenerative process and cardiovascular damage. 相似文献
10.
《The Annals of thoracic surgery》2023,115(1):88-95
BackgroundRecent guidelines for the treatment of moderate or severe ischemic mitral regurgitation (IMR) in patients undergoing coronary artery bypass grafting (CABG) have changed. This study assessed the real-world impact of changing guidelines on the management of IMR during CABG over time. We hypothesized that the utilization of mitral valve repair for IMR would decrease over time, whereas mitral valve replacement for severe IMR would increase.MethodsPatients undergoing CABG in a statewide collaborative database (2011-2020) were stratified by severity of IMR. Trends in mitral valve repair or replacement were evaluated. To account for differences of the patients, propensity score–matched analyses were used to compare patients with and without mitral intervention.ResultsA total of 11,676 patients met inclusion criteria, including 1355 (11.6%) with moderate IMR and 390 (3.3%) with severe IMR. The proportion of patients undergoing mitral intervention for moderate IMR decreased over time (2011, 17.7%; 2020, 7.5%; Ptrend = .001), whereas mitral replacement for severe IMR remained stable (2011, 11.1%; 2020, 13.3%; Ptrend = .14). Major morbidity was higher for patients with moderate IMR who underwent mitral intervention (29.1% vs 19.9%; P = .005). In a propensity analysis of 249 well-matched pairs, there was no difference in major morbidity (29.3% with mitral intervention vs 23.7% without; P = .16) or operative mortality (1.2% vs 2.4%; P = .5).ConclusionsConsistent with recent guideline updates, patients with moderate IMR were less likely to undergo mitral repair. However, the rate of replacement for severe IMR did not change. Mitral intervention during CABG did not increase operative mortality or morbidity. 相似文献